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To the Editor: In IgA nephropathy patients, Nishitani et al.1
prospectively tested the association between the number of
fibroblast-specific protein 1-positive (FSP1þ ) fibroblasts in
the renal interstitium and incident renal outcomes (i.e.
doubling in baseline serum creatinine or end-stage renal
disease), and concluded that staining FSP1þ in renal biopsy
specimens provides a valuable histologic index of progression.
The study is of interest and well conceived, but there are
major statistical problems to clarify to better understand its
potential clinical implication:
1. Apparently, the authors did not consider the treatment
imbalance (corticosteroid/renin–angiotensin system an-
tagonists) between the study groups (FSP1þ above and
below 20%) because no allowance for this potential
confounder was made in the multivariate analysis.
2. Over 8 years of follow-up, only 38 out of 142 patients
with IgA nephropathy exhibited adverse renal outcomes.
Have the authors considered as renal outcome for the
Cox analysis in Table 4 the doubling of serum creatinine
alone (n¼ 24) or both doubling of serum creatinine and
end-stage renal disease (n¼ 38)? In any case, multivariate
Cox regression analysis in this study was overtly under-
powered, because at least 100 events would have been
required to assess the independent prognostic value of
the 10 covariates included into the Cox analysis (i.e. one
variable every 10 events in the model)2. Thus, the small
number of events in this study precludes the drawing of
firm conclusions, and for this reason, more powerful
studies are needed to determine the prognostic value of
FSP1þ in IgA nephropathy patients.
1. Nishitani Y, Iwano M, Yamaguchi Y et al. Fibroblast-specific protein 1 is a
specific prognostic marker for renal survival in patients with IgAN. Kidney
Int 2005; 68: 1078–1085.
2. In: Hosmer Jr DW and Lemeshow S (eds). Applied Survival Analysis:
Regression Modeling of Time to Event Data. Wiley-Inter-science: New York,
1999.
G Parlongo1, G Tripepi1 and C Zoccali1
1CNR-IBIM, Clinical Epidemiology and Physiopathology of Renal Diseases and
Hypertension, Reggio Calabria, Italy
Correspondence: G Parlongo, CNR-IBIM, Clinical Epidemiology and
Physiopathology of Renal Diseases and Hypertension, Via Filippini no. 85,
Reggio Calabria 89125, Italy. E-mail: carmine.zoccali@tin.it
Response to Parlongo et al.
Kidney International (2006) 69, 1092. doi:10.1038/sj.ki.5000179
We thank Drs Parlongo, Tripepi, and Zoccali for their
query regarding the statistics in our paper. We feel pretty
comfortable with our original analyses based on the
biostatistical advice given during their preparation.
Technically speaking, all clinical studies never have enough
power. The power of a study, however, is usually of concern
when no differences are observed – this was not the case in
our study.
To answer the new questions asked by our correspon-
dents, in our original report, we performed multivariate
analyses for clinical parameters and for histologic para-
meters separately; therefore, the number of covariates is
not 10, but 5. Because of further questions about number
of events, we performed two additional Cox analyses with
advice from our statistician. First, using two covariates
and every possible combination (FSP1þ fibroblasts/HPF
versus gender, age, serum creatinine, hypertension, sclero-
sis, proliferation, fibrosis, or smooth muscle actin). In all
analyses, FSP1þ fibroblasts/HPF were higher and a more
significant risk factor for progression to renal failure
(range of relative risk for 420 FSP1þ fibroblasts/HPF:
8.8–16.1; Pp0.0001). Second, to consider the effect of any
treatment imbalance, we performed Cox analyses using
three parameters, (FSP1þ fibroblasts/HPF, hypertension,
with or without RAS blockers – ACEI, ARBs, or both) and
(FSP1þ fibroblasts/HPF, hypertension, with or without
corticosteroid). In all cases, the presence of FSP1þ
fibroblasts/HPF was still the higher and more significant
risk factor.
Our additional data confirm the significance of increas-
ing numbers of FSP1þ fibroblasts/HPF as a prognostic
factor of IgA nephropathy, and our findings strongly
suggest our conclusions may have predictive value.
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